Methods and compositions targeting viral and cellular ITAM motifs, and use of same in identifying compounds with therapeutic activity
This invention provides methods of treating, reducing the incidence of, and inhibiting metastasis formation of carcinomas, sarcomas, Epstein-Barr virus-induced malignancies, B cell proliferative disorders, and mast cell activation disorders, comprising administering to a subject a compound that inhibits an interaction of a first protein and an immunoreceptor tyrosine-based activation motif (ITAM) of a second protein, and screening methods for identifying ITAM-inhibitory compounds and peptides. This invention also provides peptides that inhibit signaling by ITAMs.
1. A method of inhibiting metastasis of a virally-induced cancer containing proteins with immunoreceptor tyrosine based activation motifs (ITAM) or a cancer containing proteins with immunoreceptor tyrosine based activation motifs (ITAM) in a subject, comprising administering to said subject a compound that inhibits an interaction of a first protein and an immunoreceptor tyrosine-based activation motif (ITAM) of a second protein, wherein said compound comprises a peptide containing a sequence selected from the group consisting of SEQ ID NOs: 1-5, 28, 33-35 and 39.
2. The method of claim 1 , whereby the peptide is modified via hydroxylation, amidation, esterification, formylation, gamma-carboxyglutamic acid hydroxylation, methylation, phosphorylation, sulfation, glycosylation, reduction, oxidation, disulfide modification, introduction of a thioether bond, introduction of a thiolester bond, a backbone condensation, biotinylation or a combination thereof.
3. The method of claim 1 , whereby the peptide comprises an amino acid which is a D amino acid; pyrrolidone carboxylic acid; 2-aminoadipic acid; 3-aminoadipic acid; beta-alanine; beta-aminoproprionic acid; 2-aminobutyric acid; 4-aminobutyric acid; piperidinic acid; 6-aminocaproic acid; 6-aminoheptanoic acid; 2-aminoheptanoic acid; 2-aminoisobutyric acid; 3-aminoisobutyric acid; 2-aminopimelic acid; 2,4 diaminobutyric acid; desmosine; 2,2 diaminopimelic acid; 2,3 diaminopropionic acid; N-ethylglycine; N-ethylasparagine; hydroxylysine; allo-hydroxylysine; 3-hydroxyproline; 4-hydroxyproline; isodesmosine; allo-isoleucine; N-methylglycine; sarcosine; methylisoleucine; methyllysine; methylvaline; norvaline; norleucine; 6-aminohexanoic acid; citrulline; cysteic acid; cyclohexylalanine; alpha-amino isobutyric acid; t-butylglycine; t-butylalanine; phenylglycine; an N-alpha-methyl amino acid, a C-alpha-methyl amino acid, a beta-methyl amino acid, orthinine, or a combination thereof.
4. The method of claim 1 , whereby the second protein is a viral protein.
5. The method of claim 1 , whereby the metastatic virally induced cancer is a sarcoma.
6. A method of treating B cell proliferative disorder, or a mast cell activation disorder is a subject, comprising administering to said subject a compound that inhibits an interaction of a first protein and an immunoreceptor tyrosine-based activation motif (ITAM) of a second protein, wherein said compound comprises a peptide containing a sequence selected from the group consisting of SEQ ID NOs: 1-5, 28, 33-35 and 39.
7. The method of claim 6 , whereby the peptide is modified via hydroxylation, amidation, esterification, formylation, gamma-carboxyglutamic acid hydroxylation, methylation, phosphorylation, sulfation, glycosylation, reduction, oxidation, disulfide modification, introduction of a thioether bond, introduction of a thiolester bond, a backbone condensation, biotinylation or a combination thereof.
8. The method of claim 6 , whereby the peptide comprises an amino acid which is a D amino acid; pyrrolidone carboxylic acid; 2-aminoadipic acid; 3-aminoadipic acid; beta-alanine; beta-aminoproprionic acid; 2-aminobutyric acid; 4-aminobutyric acid; piperidinic acid; 6-aminocaproic acid; 6-aminoheptanoic acid; 2-aminoheptanoic acid; 2-aminoisobutyric acid; 3-aminoisobutyric acid; 2-aminopimelic acid; 2,4 diaminobutyric acid; desmosine; 2,2 diaminopimelic acid; 2,3 diaminopropionic acid; N-ethylglycine; N-ethylasparagine; hydroxylysine; allo-hydroxylysine; 3-hydroxyproline; 4-hydroxyproline; isodesmosine; allo-isoleucine; N-methylglycine; sarcosine; methylisoleucine; methyllysine; methylvaline; norvaline; norleucine; 6-aminohexanoic acid; citrulline; cysteic acid; cyclohexylalanine; alpha-amino isobutyric acid; t-butylglycine; t-butylalanine; phenylglycine; an N-alpha-methyl amino acid, a C-alpha-methyl amino acid, a beta-methyl amino acid, orthinine, or a combination thereof.
9. The method of claim 6 , whereby the second protein is a viral protein.
10. The method of claim 1 , wherein said compound consists of a peptide selected from the group consisting of SEQ ID No: 1-5, 28, 33-35 and 39.
11. The method of claim 6 , wherein said compound consists of a peptide selected from the group consisting of SEQ ID No: 1-5, 28, 33-35 and 39.